Strides Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Strides Pharma Science Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Strides Pharma Science Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Strides Pharma from all sources in a single place.

Strides Pharma Science Ltd.

02 Apr 2026

1000.00

0.38%

Company Update

Strides Pharma Science Ltd - 532531 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Certificate in terms of regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018, for the quarter ended March 31, 2026

pdf

Strides Pharma Science Ltd.

27 Mar 2026

1000.00

0.38%

STRIDES PHARMA SCIENCE LIMITED

Buy: Strides Pharma Science Ltd.

Recommendation Target

Geojit BNP Paribas

The company reiterated its $400mn revenue target for FY28, supported by over 60 pending low-competition U.S. launches, while management remains constructive on other regulated markets, where an expanding product portfolio and new customer additions are expected to drive stronger growth and eventually scale these markets to revenue levels comparable with the U.S. business....

Geojit BNP Paribas upgraded Strides Pharma Science Ltd. to Buy with a price target of 1119.0 on 27 Mar, 2026.

Strides Pharma Science Ltd.

25 Mar 2026

1000.00

0.38%

SAST

Strides Pharma Science Ltd - 532531 - Closure of Trading Window

BSE India

Intimation regarding closure of Trading Window for the quarter and year ended March 31, 2026

pdf

Strides Pharma Science Ltd.

21 Mar 2026

1000.00

0.38%

Abu Dhabi Investment Portfolio: 6 stocks surge up to 110% in FY26, 3 fresh Q3 picks

Economic Times

The equity portfolio of the Abu Dhabi Investment Authority (ADIA), managed through its global funds, has recorded a 7% gain so far in FY26, rising from Rs 3,774 crore in March to Rs 3,910 crore as of March 20, 2026. As of the December 2025 quarter, the portfolio includes holdings in 26 publicly listed Indian companies.Despite this modest overall growth, performance has been uneven: six stocks have delivered strong gains in the 30110% range, while the majority have posted negative returns. The top four laggards have declined between 30% and 47% during FY26 to date. Additionally, three new stocks were added in the December 2025 quarter: Strides Pharma, Indigo Paints, and Tenneco Clean Air. (Data Source: ACE Equity, Trendlyne)

Strides Pharma Scien.. has an average target of 1119.00 from 1 broker.

Strides Pharma Science Ltd.

17 Mar 2026

1000.00

0.38%

Company Update

Strides Pharma Science Ltd - 532531 - Disclosure Under Regulation 30 Of SEBI Listing Regulations

BSE India

This has reference to the Press Release issued by the Company today titled - Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz. In this regard, please find enclosed herewith disclosure under Regulation 30 of SEBI Listing Regulations.

pdf

Strides Pharma Science Ltd.

17 Mar 2026

1000.00

0.38%

Company Update

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz

pdf

Strides Pharma Science Ltd.

17 Feb 2026

1000.00

0.38%

Company Update

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

BSE India

Arco Lab Private Limited, a wholly owned subsidiary of the Company, has completed acquisition of Neviton Softech Private Limited

pdf

Strides Pharma Science Ltd.

05 Feb 2026

1000.00

0.38%

Company Update

Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release …

BSE India

Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New York Inspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain

pdf